David Michael Evans

This inventor holds 25 USPTO granted patents and 6 published patent applications, plus 4 CIPO patents and 11 EPO patents, primarily in Kallikrein Inhibitors. Top assignees: Kalvista Pharmaceuticals Limited, Ferring B.v., Vantia Limited. Active years: 2005-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Michael Evans. Retrieved from https://idiyas.com/inventor/david-michael-evans

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 6)

% Patents Active = 40.0

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 11 (Patent Applications = 18)

Average Co-Inventor Count = 2.8

ph-index = 6

Forward Citations = 115(Granted Patents)

Location History:

Suthampton, GB (2008)
Southampton, GB (2005 - 2012)
Salisbury, GB (2015 - 2022)
Porton Down, GB (2021 - 2023)

Company Filing History:

15 out of 23

Kalvista Pharmaceuticals Limited

Kalvista Pharmceuticals Limited

patent

Years Active: 2005-2023

Loading Chart...

Areas of Expertise:

Enzyme Inhibitors

Plasma Kallikrein

Benzylamine Derivatives

Bicyclic Inhibitors

Heterocyclic Derivatives

FAP Inhibitors

Dipeptidyl Peptidase IV

Antidiabetic Agents

Selective Dipeptide Inhibitors

Non-Peptide GnRH Antagonists

Kallikrein Inhibitors

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11613527 - Enzyme inhibitors (2023-03-28),

2. 11242333 - Inhibitors of plasma kallikrein (2022-02-08),

3. 11198691 - N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors (2021-12-14),

4. 11180484 - Pyrazole derivatives as plasma kallikrein inhibitors (2021-11-23),

5. 11084809 - N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors (2021-08-10),

6. 11001578 - N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors (2021-05-11),

7. 10781181 - N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors (2020-09-22),

8. 10611758 - N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors (2020-04-07),

9. 10364238 - N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors (2019-07-30),

10. 10221161 - Inhibitors of plasma kallikrein (2019-03-05),

11. 9834513 - Benzylamine derivatives (2017-12-05),

12. 9738641 - Bicyclic inhibitors (2017-08-22),

13. 9670157 - Benzylamine derivatives (2017-06-06),

14. 9533987 - Heterocyclic derivates (2017-01-03),

15. 9234000 - Benzylamine derivatives as inhibitors of plasma kallikrein (2016-01-12),

Title: The Inventor David Michael Evans

Introduction: David Michael Evans is a renowned inventor based in Salisbury, United Kingdom, known for his groundbreaking contributions to various fields.

Latest Patents: David Michael Evans holds several patents in the areas of renewable energy technologies, medical devices, and consumer electronics.

Career Highlights: Throughout his career, David Michael Evans has successfully developed innovative solutions that have significantly impacted industries such as healthcare, energy, and technology. His ability to think outside the box and his dedication to creating practical inventions have earned him a reputation as a visionary inventor.

Collaborations: David Michael Evans has collaborated with leading research institutions, universities, and companies to bring his inventions to life. His collaborative efforts have resulted in the successful commercialization of several groundbreaking technologies.

Conclusion: David Michael Evans continues to push the boundaries of innovation, with a focus on creating solutions that address real-world challenges and improve the quality of life for people around the world.

Profile summary based on public USPTO records.